Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia
Table 1
The clinical characteristics of early-onset preeclamptic (earlyPre) and late-onset preeclamptic (latePre) patients and control subjects.
Early-onset preeclamptic patients [earlyPre] ()
Late-onset preeclampsia [latePre] ()
Healthy controls () [control group]
p value
Age (years)
30.66 ± 5.76
28.89 ± 4.61
29.45 ± 4.02
Gravidity
2.13 ± 1.73
1.52 ± 0.89
1.46 ± 0.68
Parity
1.87 ± 1.61
1.40 ± 0.76
1.38 ± 0.56
Height (cm)
164.26 ± 5.64
164.29 ± 6.22
165.04 ± 5.72
Maternal weight (kg)
83.64 ± 15.43
82.92 ± 14.50
76.38 ± 13.16
BMI (kg/m2)
30.78 ± 4.29
30.62 ± 4.65
28.05 ± 4.41
Systolic blood pressure (mmHg)
165.37 ± 15.28
166.50 ± 18.41
112.51 ± 10.32
Diastolic blood pressure (mmHg)
109.52 ± 9.75
108.72 ± 9.20
71.92 ± 7.33
Mean arterial blood pressure, MAPII (mmHg)
128.12 ± 10.53
127.97 ± 11.09
85.09 ± 8.31
Gestational age at birth (weeks)
30.31 ± 2.41
37.30 ± 1.91
38.18 ± 1.41
Birth weight (g)
1262.42 ± 437.89
2654.50 ± 713.31
3041.07 ± 527.07
MMP-2 (ng/mL)
242.93 ± 68.64 Median 235.26 (136.88–466.90)
234.39 ± 79.18 Median 219.17 (124.19–514.79)
195.30 ± 43.53 Median 189.95 (103.88–347.83)
MMP-3 (ng/mL)
63.54 ± 71.58 Median 37.115 (13.65–314.14)
27.91 ± 24.99 Median 18.04 (4.16–124.17)
29.31 ± 58.79 Median 16.749 (2.046–454.53)
MMP-9 (ng/mL)
1450.12 ± 838.01 Median 1153.32 (243.68–3383.13)
1450.86 ± 1165.903 Median 1040.2 (325.07–6430.0)
1752.53 ± 901.54 Median 1605.75 (336.83–4569.2)
MMP-13 (ng/mL)
0.590 ± 0.681 Median 0.407 (0.054–4.351)
0.482 ± 0.278 Median 0.385 (0.008–1,264)
0.427 ± 0.228 Median 0.409 (0.014–1.047)
Values are reported as mean ± standard deviation (SD) or median and minimum–maximum; MMP-2: matrix metalloproteinase-2; MMP-3: matrix metalloproteinase-3; MMP-9: matrix metalloproteinase-9; MMP-13: matrix metalloproteinase-13; BMI body mass index (calculated as weight in kilograms divided by the square of height in meters) kg/m2. Statistical significance (); groups of studied pregnant women: control group: healthy normotensive pregnant women; earlyPre group: patients with pregnancy complicated by early-onset severe preeclampsia; latePre group: women with pregnancy complicated by late-onset severe preeclampsia.
